Моделі скринінгу та прогнозу прогресування хронічної хвороби нирок

  • М.О. Колесник Державна установа «Національний науковий центр хірургії та трансплантології імені О.О. Шалімова НАМН України», Київ, Україна https://orcid.org/0000-0001-6658-3729
  • Л.В. Король Державна установа «Національний науковий центр хірургії та трансплантології імені О.О. Шалімова НАМН України», Київ, Україна https://orcid.org/0000-0002-5484-0326
  • І.В. Шуба Навчально-науковий інститут високих технологій Київського національного університету імені Тараса Шевченка, Київ, Україна
DOI: https://doi.org/10.31450/ukrjnd.3(91).2026.11
Ключові слова: хронічна хвороба нирок; скринінг; швидкість клубочкової фільтрації; альбумінурія; клінічні алгоритми.

Анотація

Перебіг хронічої хвороби нирок (ХХН) на ранніх стадіях, як правило, безсимптомний, тому у значної частки пацієнтів хвороба діагностовується інцедентально або у разі появи клінічних проявів (гіпертензія, набряки і т.п.).  Сучасний підхід до стратифікації ризиків, діагностики, оцінки прогресування ХХН базується на  аналізі співвідношення  розрахункової швидкості клубочкової фільтрації (eGFR) та альбумінурії (передусім співвідношення альбумін-креатинін, ACR) з використанням валідованих калькуляторів. У роботі оцінені калькулятори для встановлення імовірності формування  ХХН (SCORED, QKidney, CKD-PC Incident CKD Risk) та її прогресування (Kidney Failure Risk Equation, KFRE).

Продемонстровано, що найбільш клінічно корисною є послідовність: ризик-орієнтований відбір пацієнтів для тестування, підтвердження наявності ХХН за eGFR та ACR, оцінка темпу прогресування у хворих на ХХН G3-G5 за KFRE. Запропоновано  практичний алгоритм застосування цих інструментів для сімейних лікарів та лікарів-нефрологів.

Завантаження

Дані завантаження ще не доступні.

Посилання

Sundström J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. CaReMe CKD Investigators. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: the CaReMe CKD study. Lancet Reg Health Eur. 2022; 20:100438. doi: 10.1016/j.lanepe.2022.100438.

Chertow GM, Correa-Rotter R, Eckardt KU, Kanda E, Karasik A, Li G, et al Projecting the clinical burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study. EClinicalMedicine. 2024;72:102614. doi: 10.1016/j.eclinm.2024.102614.

van Mil D, Kieneker LM, Heerspink HJL, Gansevoort RT. Screening for chronic kidney disease: change of perspective and novel developments. Curr Opin Nephrol Hypertens. 2024;33(6):583-92. doi: 10.1097/MNH.0000000000001016.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.

National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. NICE guideline NG203 [Internet]. London: NICE; 2021. Available from: https://www.nice.org.uk/guidance/ng203/chapter/recommendations.

Bang H, Vupputuri S, Shoham DA, Klemmer PJ, Falk RJ, Mazumdar M, et al. SCreening for Occult REnal Disease (SCORED): A Simple Prediction Model for Chronic Kidney Disease. Arch Intern Med. 2007;167(4):374-81. doi: 10.1001/archinte.167.4.374.

Ramspek CL, de Jong Y, Dekker FW, van Diepen M. Towards the best kidney failure prediction tool: a systematic review and selection aid. Nephrol Dial Transplant. 2020;35(9):1527-38. doi: 10.1093/ndt/gfz018.

Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, et al. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. JAMA. 2016;315(2):164-74. doi: 10.1001/jama.2015.18202.

Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-49. doi: 10.1056/NEJMoa2102953.

National Kidney Foundation. eGFR Calculator [Internet]. New York: National Kidney Foundation; Available from: https://www.kidney.org/professionals/gfr_calculator.

National Institute of Diabetes and Digestive and Kidney Diseases. Estimated Glomerular Filtration Rate Calculators [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2024 May. Available from: https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/kidney-disease/laboratory-evaluation/estimated-gfr-calculators.

Vaidya SR, Aeddula NR. Chronic Kidney Disease. [Updated 2024 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535404/.

Levin A, Ahmed S, Carrero JJ, Foster B, Francis A, Hall RK, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684-701. doi: 10.1016/j.kint.2023.10.016.

Forbes A, Gallagher H. Chronic kidney disease in adults: assessment and management. Clin Med (Lond). 2020 Mar 18;20(2):128-32. doi: 10.7861/clinmed.cg.20.2.

Centers for Disease Control and Prevention. Chronic Kidney Disease Risk Calculators [Internet]. Atlanta (GA): CDC. Available from: https://wwwn.cdc.gov/kdss/Calculators.aspx.

Bang H, Mazumdar M, Newman G, Bomback AS, Ballantyne CM, Jaffe AS, et al. Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience. Nephrol Dial Transplant. 2009,24(8):2452-7. doi: 10.1093/ndt/gfp124.

Carrillo-Larco RM, Miranda JJ, Gilman RH, Medina-Lezama J, Chirinos-Pacheco JA, Muñoz-Retamozo PV, et al. Risk score for first-screening of prevalent undiagnosed chronic kidney disease in Peru: the CRONICAS-CKD risk score. BMC Nephrol. 2017;18(1):343. doi: 10.1186/s12882-017-0758-4.

Hippisley-Cox J, Coupland C. Predicting the risk of Chronic Kidney Disease in Men and Women in England and Wales: prospective derivation and external validation of the QKidney®Scores. BMC Fam Pract 2010;11:49. doi: 10.1186/1471-2296-11-49.

QResearch. QKidney – predicting the risk of chronic kidney disease [Internet]. Oxford: QResearch. Available from: https://www.qresearch.org/research/research-programs-and-projects/qkidney-predicting-the-risk-of-chronic-kidney-disease/.

QKidney. QKidney risk calculator [Internet]. Available from: http://qkidney.org.

Nelson RG, Grams ME, Ballew SH, Sang Y, Azizi F, Chadban SJ, et al. CKD Prognosis Consortium. Development of Risk Prediction Equations for Incident Chronic Kidney Disease. JAMA. 2019;322(21):2104-14. doi: 10.1001/jama.2019.17379.

Chronic Kidney Disease Prognosis Consortium. CKD Risk Tool: risk of incident chronic kidney disease [Internet]. Available from: https://ckdpcrisk.org/ckdrisk.

Кawasoe S, Kubozono T, Salim AA, Yoshimine H, Mawatari S, Ojima S, et al. Development of a risk prediction score and equation for chronic kidney disease: a retrospective cohort study. Sci Rep. 2023;13:5001. doi: 10.1038/s41598-023-32279-z.

Jhamb M, Weltman MR, Yabes JG, Kamat S, Devaraj SM, Fischer GS, et al. Electronic health record based population health management to optimize care in CKD: Design of the Kidney Coordinated HeAlth Management Partnership (K-CHAMP) trial. Contemp Clin Trials. 2023;131:107269. doi: 10.1016/j.cct.2023.107269.

Jolly SE, Navaneethan SD, Schold JD, Arrigain S, Sharp JW, Jain AK, et al. Chronic kidney disease in an electronic health record problem list: quality of care, ESRD, and mortality. Am J Nephrol. 2014;39(4):288-96. doi: 10.1159/000360306.

Fernández-Llaneza D, Hilbrands LB, Vogt L, Engberink RHGO, Klopotowska JE, the LEAPfROG Consortium. Identifying a cohort of hospitalized chronic kidney disease patients using electronic health records: lessons learnt and implications for future research and clinical practice guidelines. Clin Kidney J. 2025;18(4): sfaf073. doi: 10.1093/ckj/sfaf073.

Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553-59. doi: 10.1001/jama.2011.451.

Chronic Kidney Disease Prognosis Consortium. The Kidney Failure Risk Equation [Internet]. Available from: https://www.kidneyfailurerisk.com/.

MDCalc. Kidney Failure Risk Calculator [Internet]. New York: MDCalc; Available from: https://www.mdcalc.com/calc/10045/kidney-failure-risk-calculator.

Major RW, Shepherd D, Medcalf JF, Xu G, Gray LJ, Brunskill NJ. Correction: The Kidney Failure Risk Equation for prediction of end stage renal disease in UK primary care: An external validation and clinical impact projection cohort study. PLOS Medicine 2020;17(7):e1003313. doi: 10.1371/journal.pmed.1003313.

UK Kidney Association. Kidney Failure Risk Equation (KFRE): quick reference [Internet]. Bristol: UK Kidney Association. Available from: https://www.ukkidney.org/sites/default/files/education/KFRE%20quick%20reference.pdf.

Grams ME, Brunskill NJ, Ballew SH, Sang Y, Coresh J, Matsushita K, et al.The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts. J Am Soc Nephrol. 2023;34(3):482-94. doi: 10.1681/ASN.0000000000000050.

Zacharias HU, Altenbuchinger M, Schultheiss UT, Raffler J, Kotsis F, Ghasemi S, et al. A Predictive Model for Progression of CKD to Kidney Failure Based on Routine Laboratory Tests. Am J Kidney Dis. 2022;79(2):217-30.e1. doi: 10.1053/j.ajkd.2021.05.018.

Zheng S, Parikh RV, Tan TC, Pravoverov L, Patel JK, Horiuchi KM, Go A. CKD stage-specific utility of two equations for predicting 1-year risk of ESKD. SPLoS One. [Internet]. 2023;18(11):e0293293. Available from: https://divisionofresearch.kaiserpermanente.org/publications/ckd-stage-specific-utility-of-two-equations-for-predicting-1-year-risk-of-eskd/.

Park KJ, Tandy MK, Flerchinger S, Glassberg KJ, Chen FY, Albright ES, et al. Improving CKD Screening and Care in Diabetes Using Clinical Decision Support in a Large Health Care System. Kidney360. 2025;6(9):1501-09 doi: 10.34067/KID.0000000829.

Grams ME, Sang Y, Ballew SH, Carrero JJ, Djurdjev O, Heerspink HJL, et al. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93(6):1442-51. doi: 10.1016/j.kint.2018.01.009.

Chronic Kidney Disease Prognosis Consortium. Clinical outcomes in CKD [Internet]. Available from: https://www.ckdpcrisk.org/lowgfrevents/.

Evans M, Grams ME, Sang Y, Astor BC, Blankestijn PJ, Brunskill NJ, et al. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3(3): 625-37. doi: 10.1016/j.ekir.2018.01.002.

Gallego-Valcarce E, Shabaka A, Tato-Ribera AM, Landaluce-Triska E, León-Poo M, Roldan D, Gruss E. External validation of the KFRE and Grams prediction models for kidney failure and death in a Spanish cohort of patients with advanced chronic kidney disease. J Nephrol. 2024;37(2):429-37. doi: 10.1007/s40620-023-01819-1.

Thanabalasingam S, Iliescu E, Norman P, Akbari A, Hundemer GL, White CA. Independent External Validation and Comparison of Death and Kidney Replacement Therapy Prediction Models in Advanced CKD. Kidney Med. 2022; 4(4):100440. doi: 10.1016/j.xkme.2022.100440.

Chien KL, Lin HJ, Lee BC, Hsu HC, Lee YT, Chen MF. A prediction model for the risk of incident chronic kidney disease. Am J Med. 2010;123(9):836-46.e2. doi: 10.1016/j.amjmed.2010.05.010.

Klinrisk. The Science of Klinrisk [Internet]. Available from: https://www.klinrisk.com/thescience.

Tangri N, Ferguson T, Leon SJ, Anker SD, Filippatos G, Pitt B, et al. Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population. Clin Kidney J. 2024;17(4):sfae 052. doi: 10.1093/ckj/sfae052.

Oshima M, Gosho M, Iwagami M, Sugawara Y, Nagasu H, Kuwabara T, et al. Review no. 2: a beginner’s guide for calculating eGFR slope using linear mixed-effects model in R—step-by-step methods and code examples. Clin Exp Nephrol. 2026;30(4):545-58. doi: 10.1007/s10157-026-02835-8.

The European Medicines Agency. Qualification opinion for GFR slope as a validated surrogate endpoint for RCT in CKD. [Internet]. Available from: https://www.ema.europa.eu/en/documents/other/qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf. First published 21 Dec 2023. Accessed 20 Feb 2026.

Nickerson PW. What have we learned about how to prevent and treat antibody-mediated rejection in kidney transplantation? Am J Transplant. 2020:20 Suppl 4:12-22. doi: 10.1111/ajt.15859.

Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020:75(1):84-104. doi: 10.1053/j.ajkd.2019.06.009.

Іmaizumi T, Komaba H, Hamano T, Nangaku M, Murotani K, Hasegawa T, et al. Clinically meaningful eGFR slope as a surrogate endpoint differs across CKD stages and slope evaluation periods: the CKD-JAC study. Clin Kidney J. 2025;18(2):sfae398. doi: 10.1093/ckj/sfae398.

Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023:29(7):1867-76. doi: 10.1038/s41591-023-02418-0.

Grams ME, Brunskill NJ, Ballew SH, Sang Y, Coresh J, Matsushita K, et al. Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes. Diabetes Care. 2022;45(9):2055-63. doi: 10.2337/dc22-0698.

Schroeder EB, Yang X, Thorp ML, Arnold BM, Tabano DC, Petrik AF, et al. Predicting 5-Year Risk of RRT in Stage 3 or 4 CKD: Development and External Validation. Clin J Am Soc Nephrol. 2017;12(1):87-94. doi: 10.2215/CJN.01290216.

U.S. Food and Drug Administration. De Novo classification request for KidneyIntelX.dkd, DEN200052 [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2023 Jun 29. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN200052.pdf.

MDCalc. International IgA Nephropathy Prediction Tool [Internet]. New York: MDCalc. Available from: https://www.mdcalc.com/calc/10533/international-iga-nephropathy-prediction-tool.

Cornec-Le Gall E, Audrézet M-Р, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016;27(3):942-51. doi: 10.1681/ASN.2015010016.

AJKD Blog. Clinical Trial End Points in ADPKD [Internet]. New York: National Kidney Foundation; 2019 Jun 6. Avalable from: https://ajkdblog.org/2019/06/06/clinical-trial-end-points-in-adpkd/.

ADPKDSim. Prognostic tools: PROPKD Score [Internet]. Available from: https://adpkdsim.org/expert/prognostic-tools/propkd-score.

Allmer DM, Parada Rodriguez D, Aigner C, Laccone F, Nagel M, Metz-Schimmerl S, Sunder-Plassmann G. Progression to kidney failure in ADPKD: the PROPKD score underestimates the risk assessed by the Mayo imaging classification. Front. Med. 2024:11:1470309. doi: 10.3389/fmed.2024.1470309.

Ministerstvo okhorony zdorovia Ukrainy. Nastanova 00226. Likuvannia khronichnoi khvoroby nyrok [Internet]. Kyiv: MOZ Ukrainy; 2017-02-06. Dostupno: https://guidelines.moz.gov.ua/documents/3114. [In Ukrainian].

Writing Group for the CKD Prognosis Consortium. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis. JAMA. 2023;330(13):1266-77. doi: 10.1001/jama.2023.17002.

Du Y, Wang K. Machine Learning Prediction of Chronic Kidney Disease in Elderly MetS Patients Using NHANES 2011-2020 Data. Rejuvenation Res. 2026;29(2):62-72. doi: 10.1177/15491684251399607.


Переглядів анотації: 3
Завантажень PDF: 0
Опубліковано
2026-08-28
Як цитувати
Колесник, М., Король, Л., & Шуба , І. (2026). Моделі скринінгу та прогнозу прогресування хронічної хвороби нирок. Український Журнал Нефрології та Діалізу, (3(91), 104-122. https://doi.org/10.31450/ukrjnd.3(91).2026.11
Номер
№ 3(91) (2026): Український журнал нефрології та діалізу
Розділ
Школа нефролога

Авторське право (c) 2026 Український Журнал Нефрології та Діалізу

Creative Commons License

TЦя робота ліцензується відповідно до Creative Commons Attribution-ShareAlike 4.0 International License.